Bicara Therapeutics Inc.
BCAXDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
BCAX Earnings Report
EPS Est: $-0.77 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How BCAX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ficerafusp alfa | Phase 3 | Metastatic Head and Neck Squamous Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bicara Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Bicara Therapeutics Inc.'s (BCAX) pipeline across Phase 3. Its lead program is Ficerafusp alfa (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bicara Therapeutics Inc.'s next FDA catalyst?→
Bicara Therapeutics Inc.'s (BCAX) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCAX biotech catalysts?→
Add BCAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bicara Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.